Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Notes underwriting agrmnt
Inv. presentation
Asset disposition
Appointed CFO
Quarterly results
Director departure
Appointed director
ARCA biopharma, Inc. (ABIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/21/2023 8-K Quarterly results
04/24/2023 8-K Quarterly results
02/24/2023 8-K Quarterly results
Docs: "ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ • Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Westminster, CO, February 24, 2023 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2022 financial results and provided a corporate update. In May 2022, the Company retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor to explore and evaluate strategic options for maximizing stockholder value. Potentia..."
02/13/2023 8-K Quarterly results
12/19/2022 8-K Quarterly results
12/09/2022 8-K Quarterly results
10/28/2022 8-K Quarterly results
10/20/2022 8-K Quarterly results
08/02/2022 8-K Quarterly results
Docs: "Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Westminster, CO, August 2, 2022 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We are in the process of evaluating options for creating stockholder value, including potential development of our assets, partnering and other strategic options.” In May 2022, the Company retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor to explore and evaluate s..."
06/21/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
05/02/2022 8-K Quarterly results
04/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ARCA biopharma Establishes Special Committee of the Board of Directors"
03/14/2022 8-K Quarterly results
12/16/2021 8-K Quarterly results
12/02/2021 8-K Quarterly results
11/02/2021 8-K Quarterly results
Docs: "ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------"
10/28/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Enrollment completion anticipated by year end 2021 • Topline data anticipated in first quarter of 2022 Westminster, CO, October 28, 2021 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today provided an update on the ASPEN‑COVID‑19 Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with severe COVID-19. The Company announced that the Data and Safety Monitoring Committee has completed a pre-specified interim analysis and, based on the DSMC’s review of approximately 75% of the projected final efficacy and safety data, recommended completion of the clinical trial with no modifications to the trial design. The rNAPc2 develop..."
09/16/2021 8-K Quarterly results
08/09/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2"
08/04/2021 8-K Quarterly results
Docs: "Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID‑19 expanded to South America • Topline data anticipated in the fourth quarter of 2021 Westminster, CO, August 4, 2021 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2021 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We continue to be encouraged with the opportunities we see in our development pipeline compounds, rNAPc2 and Gencaro. With the ASPEN-COVID-19 Phase 2b trial of rNAPc2 expanding to South America, we look forward to completing the trial and we anticipate sharing the res..."
07/28/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology"
07/13/2021 8-K Quarterly results
07/09/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
07/07/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Provides exclusive world-wide patent rights to the use of rNAPc2 as a potential treatment for COVID‑19 and other indications"
06/28/2021 8-K Quarterly results
06/28/2021 8-K Quarterly results
06/10/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
05/03/2021 8-K Quarterly results
04/06/2021 8-K Quarterly results
03/18/2021 8-K Quarterly results
Docs: "Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID‑19 anticipated in the third quarter of 2021 • New patent issued by USPTO for use of Gencaro in treating atrial fibrillation in heart failure patients with ejection fractions greater than 40% Westminster, CO, March 18, 2021 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2020 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We are currently actively enrolling patients in a Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19 who..."
02/02/2021 8-K Quarterly results
12/23/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Standard)",
"Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Officer)",
"Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Director)",
"Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2020 Equity Incentive Plan (Standard)",
"Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2020 Equity Incentive Plan (Officer)"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy